Overview

* Cardiff Oncology ( CRDF ) Q2 net loss of $13.9 mln widens

* Operating expenses rose due to clinical trial costs and new hires

* Completed enrollment in Phase 2 trial for first-line RAS-mutated mCRC

Outlook

* Cardiff Oncology projects cash runway into Q1 2027

Result Drivers

* TRIAL ENROLLMENT - Completion of enrollment in Phase 2 CRDF-004 trial for first-line RAS-mutated mCRC

* OPERATING EXPENSES - Increase due to clinical trial costs and new hires

* POSITIVE TRIAL DATA - Announced positive data from onvansertib and paclitaxel trial in mTNBC

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $121,000

Royalty

Revenue

Q2 Net Miss -$13.94 -$13.50

Income mln mln (8

Analysts

)

Q2 Miss -$14.78 -$14.10

Income mln mln (8

from Analysts

Operatio )

ns

Q2 Basic -$0.21

EPS

Q2 $14.90

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Cardiff Oncology Inc ( CRDF ) is $12.00, about 68.9% above its July 28 closing price of $3.73

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)